Postmenopause: The physiological period following the MENOPAUSE, the permanent cessation of the menstrual life.Perimenopause: The transitional period before and after MENOPAUSE. Perimenopausal symptoms are associated with irregular MENSTRUAL CYCLE and widely fluctuated hormone levels. They may appear 6 years before menopause and subside 2 to 5 years after menopause.Smegma: A foul-smelling accumulation of SEBUM and desquaminated epidermal cells, especially the cheesy substance found under the foreskin of the penis and at the base of the labia minor near the clitoris.Hot Flashes: A sudden, temporary sensation of heat predominantly experienced by some women during MENOPAUSE. (Random House Unabridged Dictionary, 2d ed)Premenopause: The period before MENOPAUSE. In premenopausal women, the climacteric transition from full sexual maturity to cessation of ovarian cycle takes place between the age of late thirty and early fifty.Estrogen Replacement Therapy: The use of hormonal agents with estrogen-like activity in postmenopausal or other estrogen-deficient women to alleviate effects of hormone deficiency, such as vasomotor symptoms, DYSPAREUNIA, and progressive development of OSTEOPOROSIS. This may also include the use of progestational agents in combination therapy.Women's Health: The concept covering the physical and mental conditions of women.Follicle Stimulating Hormone: A major gonadotropin secreted by the adenohypophysis (PITUITARY GLAND, ANTERIOR). Follicle-stimulating hormone stimulates GAMETOGENESIS and the supporting cells such as the ovarian GRANULOSA CELLS, the testicular SERTOLI CELLS, and LEYDIG CELLS. FSH consists of two noncovalently linked subunits, alpha and beta. Within a species, the alpha subunit is common in the three pituitary glycoprotein hormones (TSH, LH, and FSH), but the beta subunit is unique and confers its biological specificity.Longitudinal Studies: Studies in which variables relating to an individual or group of individuals are assessed over a period of time.Aging: The gradual irreversible changes in structure and function of an organism that occur as a result of the passage of time.Risk Factors: An aspect of personal behavior or lifestyle, environmental exposure, or inborn or inherited characteristic, which, on the basis of epidemiologic evidence, is known to be associated with a health-related condition considered important to prevent.Obstetrics: A medical-surgical specialty concerned with management and care of women during pregnancy, parturition, and the puerperium.Menopause: The last menstrual period. Permanent cessation of menses (MENSTRUATION) is usually defined after 6 to 12 months of AMENORRHEA in a woman over 45 years of age. In the United States, menopause generally occurs in women between 48 and 55 years of age.Endocrinology: A subspecialty of internal medicine concerned with the metabolism, physiology, and disorders of the ENDOCRINE SYSTEM.Menopause, Premature: The premature cessation of menses (MENSTRUATION) when the last menstrual period occurs in a woman under the age of 40. It is due to the depletion of OVARIAN FOLLICLES. Premature MENOPAUSE can be caused by diseases; OVARIECTOMY; RADIATION; chemicals; and chromosomal abnormalities.Spondylolisthesis: Forward displacement of a superior vertebral body over the vertebral body below.Intervertebral Disc Displacement: An INTERVERTEBRAL DISC in which the nucleus pulposus has protruded through surrounding fibrocartilage. This occurs most frequently in the lower lumbar region.Spinal Stenosis: Narrowing of the spinal canal.Hydroxyzine: A histamine H1 receptor antagonist that is effective in the treatment of chronic urticaria, dermatitis, and histamine-mediated pruritus. Unlike its major metabolite CETIRIZINE, it does cause drowsiness. It is also effective as an antiemetic, for relief of anxiety and tension, and as a sedative.Internet: A loose confederation of computer communication networks around the world. The networks that make up the Internet are connected through several backbone networks. The Internet grew out of the US Government ARPAnet project and was designed to facilitate information exchange.Oxycodone: A semisynthetic derivative of CODEINE.Dictionaries, MedicalDictionaries as Topic: Lists of words, usually in alphabetical order, giving information about form, pronunciation, etymology, grammar, and meaning.Diabetes Mellitus: A heterogeneous group of disorders characterized by HYPERGLYCEMIA and GLUCOSE INTOLERANCE.Diabetes Mellitus, Type 1: A subtype of DIABETES MELLITUS that is characterized by INSULIN deficiency. It is manifested by the sudden onset of severe HYPERGLYCEMIA, rapid progression to DIABETIC KETOACIDOSIS, and DEATH unless treated with insulin. The disease may occur at any age, but is most common in childhood or adolescence.Diabetes Mellitus, Type 2: A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.Diet, Vegetarian: Dietary practice of completely avoiding meat products in the DIET, consuming VEGETABLES, CEREALS, and NUTS. Some vegetarian diets called lacto-ovo also include milk and egg products.Meat: The edible portions of any animal used for food including domestic mammals (the major ones being cattle, swine, and sheep) along with poultry, fish, shellfish, and game.Weight Gain: Increase in BODY WEIGHT over existing weight.Diet, Reducing: A diet designed to cause an individual to lose weight.Body Weight: The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.Dietary Supplements: Products in capsule, tablet or liquid form that provide dietary ingredients, and that are intended to be taken by mouth to increase the intake of nutrients. Dietary supplements can include macronutrients, such as proteins, carbohydrates, and fats; and/or MICRONUTRIENTS, such as VITAMINS; MINERALS; and PHYTOCHEMICALS.Vitamin D: A vitamin that includes both CHOLECALCIFEROLS and ERGOCALCIFEROLS, which have the common effect of preventing or curing RICKETS in animals. It can also be viewed as a hormone since it can be formed in SKIN by action of ULTRAVIOLET RAYS upon the precursors, 7-dehydrocholesterol and ERGOSTEROL, and acts on VITAMIN D RECEPTORS to regulate CALCIUM in opposition to PARATHYROID HORMONE.Strikes, Employee: Work-related situations in which the employees as a group refuse to work until certain conditions of employment are granted by the employer.Calcium, Dietary: Calcium compounds used as food supplements or in food to supply the body with calcium. Dietary calcium is needed during growth for bone development and for maintenance of skeletal integrity later in life to prevent osteoporosis.Osteoporosis: Reduction of bone mass without alteration in the composition of bone, leading to fractures. Primary osteoporosis can be of two major types: postmenopausal osteoporosis (OSTEOPOROSIS, POSTMENOPAUSAL) and age-related or senile osteoporosis.Vitamins: Organic substances that are required in small amounts for maintenance and growth, but which cannot be manufactured by the human body.Bone and Bones: A specialized CONNECTIVE TISSUE that is the main constituent of the SKELETON. The principle cellular component of bone is comprised of OSTEOBLASTS; OSTEOCYTES; and OSTEOCLASTS, while FIBRILLAR COLLAGENS and hydroxyapatite crystals form the BONE MATRIX.Ovary: The reproductive organ (GONADS) in female animals. In vertebrates, the ovary contains two functional parts: the OVARIAN FOLLICLE for the production of female germ cells (OOGENESIS); and the endocrine cells (GRANULOSA CELLS; THECA CELLS; and LUTEAL CELLS) for the production of ESTROGENS and PROGESTERONE.Leiomyoma: A benign tumor derived from smooth muscle tissue, also known as a fibroid tumor. They rarely occur outside of the UTERUS and the GASTROINTESTINAL TRACT but can occur in the SKIN and SUBCUTANEOUS TISSUE, probably arising from the smooth muscle of small blood vessels in these tissues.Virilism: Development of male secondary SEX CHARACTERISTICS in the FEMALE. It is due to the effects of androgenic metabolites of precursors from endogenous or exogenous sources, such as ADRENAL GLANDS or therapeutic drugs.Uterine Neoplasms: Tumors or cancer of the UTERUS.Thecoma: A gonadal stromal neoplasm composed only of THECA CELLS, occurring mostly in the postmenopausal OVARY. It is filled with lipid-containing spindle cells and produces ESTROGENS that can lead to ENDOMETRIAL HYPERPLASIA; UTERINE HEMORRHAGE; or other malignancies in postmenopausal women and sexual precocity in girls. When tumors containing theca cells also contain FIBROBLASTS, they are identified as thecoma-fibroma tumors with less active hormone production.Weight Loss: Decrease in existing BODY WEIGHT.Obesity: A status with BODY WEIGHT that is grossly above the acceptable or desirable weight, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).Cognitive Dissonance: Motivational state produced by inconsistencies between simultaneously held cognitions or between a cognition and behavior; e.g., smoking enjoyment and believing smoking is harmful are dissonant.Diet: Regular course of eating and drinking adopted by a person or animal.ArchivesBiological Science Disciplines: All of the divisions of the natural sciences dealing with the various aspects of the phenomena of life and vital processes. The concept includes anatomy and physiology, biochemistry and biophysics, and the biology of animals, plants, and microorganisms. It should be differentiated from BIOLOGY, one of its subdivisions, concerned specifically with the origin and life processes of living organisms.Periodicals as Topic: A publication issued at stated, more or less regular, intervals.PubMed: A bibliographic database that includes MEDLINE as its primary subset. It is produced by the National Center for Biotechnology Information (NCBI), part of the NATIONAL LIBRARY OF MEDICINE. PubMed, which is searchable through NLM's Web site, also includes access to additional citations to selected life sciences journals not in MEDLINE, and links to other resources such as the full-text of articles at participating publishers' Web sites, NCBI's molecular biology databases, and PubMed Central.Directories as Topic: Lists of persons or organizations, systematically arranged, usually in alphabetic or classed order, giving address, affiliations, etc., for individuals, and giving address, officers, functions, and similar data for organizations. (ALA Glossary of Library and Information Science, 1983)

Glutathione-S-transferase (GSTM1) genetic polymorphisms do not affect human breast cancer risk, regardless of dietary antioxidants. (1/3881)

Glutathione-S-transferases catalyze the detoxication of carcinogen metabolites and reactive oxygen species (ROS) produced through a number of mechanisms. Glutathione-S-transferase (GST) M1 is polymorphic, and the null allele results in a lack of enzyme activity. Because there are indications that ROS may be involved in breast carcinogenesis, we sought to determine whether the GSTM1 null allele was associated with increased breast cancer, particularly among women with lower consumption of dietary sources of alpha-tocopherol, carotenoids and ascorbic acid. In a study of diet and cancer in western New York, women with primary, incident, histologically confirmed breast cancer (n = 740) and community controls (n = 810) were interviewed and an extensive food-frequency questionnaire administered. A subset of these women provided a blood specimen. DNA was extracted and genotyping performed for GSTM1. Data were available for 279 cases and 340 controls. The null allele did not increase breast cancer risk, regardless of menopausal status. There were also no differences in associations between the polymorphism and risk among lower and higher consumers of dietary sources of antioxidants or smokers and nonsmokers. These results indicate that GSTM1 genetic polymorphisms are not associated with breast cancer risk, even in an environment low in antioxidant defenses.  (+info)

Tumour necrosis factor-alpha (TNF-alpha) in human endometrium and uterine secretion: an evaluation by immunohistochemistry, ELISA and semiquantitative RT-PCR. (2/3881)

Tumour necrosis factor-alpha (TNF-alpha is a pleiotropic cytokine synthesized throughout the female reproductive tract. Even though evidence has accumulated that supports its role in autocrine and paracrine processes, its expression and function in the human endometrium are still not completely understood. To gain a better understanding of the synthesis and release of TNF-alpha in the endometrium and how this relates to concentrations in uterine secretion, its expression throughout the menstrual cycle was investigated by three different techniques. Samples of endometrial tissue and uterine secretions were collected from patients undergoing abdominal and vaginal hysterectomy for benign reasons. The mRNA expression of TNF-alpha was investigated in homogenized endometrial tissue by semiquantitative reverse transcription-polymerase chain reaction (RT-PCR) (n = 18). An assessment of the cellular TNF-alpha protein localization in the endometrial glands was performed immunohistochemically (n = 39). The concentrations of the secreted TNF-alpha protein in endometrial secretion were determined by enzyme-linked immunosorbent analysis (n = 30). All three methods gave similar results on the temporal expression of TNF-alpha mRNA and TNF-alpha protein during the cycle. Concentrations of endometrial TNF-alpha mRNA in tissue samples and TNF-alpha protein in uterine secretion were quite low at the beginning of the cycle, rose sharply in the mid- to late proliferative phase and decreased towards the end of the cycle. The concentrations of TNF-alpha protein in the endometrial glands, as shown by immunohistochemical investigation, stayed high throughout the secretory phase at values slightly below those of the late proliferative phase.  (+info)

Cyclical etidronate increases bone density in the spine and hip of postmenopausal women receiving long term corticosteroid treatment. A double blind, randomised placebo controlled study. (3/3881)

OBJECTIVE: To study the effect of cyclic etidronate in secondary prevention of corticosteroid induced osteoporosis. METHODS: A double blind, randomised placebo controlled study comparing cyclic etidronate and placebo during two years in 37 postmenopausal women receiving long term corticosteroid treatment, mainly for polymyalgia rheumatica (40% of the patients) and rheumatoid arthritis (30%). Bone density was measured in the lumbar spine, femoral neck, and femoral trochanter. RESULTS: After two years of treatment there was a significant difference between the groups in mean per cent change from baseline in bone density in the spine in favour of etidronate (p = 0.003). The estimated treatment difference (mean (SD)) was 9.3 (2.1)%. Etidronate increased bone density in the spine (4.9 (2.1)%, p < 0.05) whereas the placebo group lost bone (-2.4 (1.6)%). At the femoral neck there was an estimated difference of 5.3 (2.6)% between the groups (etidronate: 3.6% (1.4)%, p < 0.05, placebo: -2.4 (2.1)%). The estimated difference at the trochanter was 8.2 (3.0) (etidronate: 9.0 (1.5)%, p < 0.0001, placebo: 0.5 (2.3)%). No significant bone loss occurred in the hip in placebo treated patients. CONCLUSIONS: Cyclic etidronate is an effective treatment for postmenopausal women receiving corticosteroid treatment and is well tolerated.  (+info)

Expression of prostate-specific antigen (PSA) correlates with poor response to tamoxifen therapy in recurrent breast cancer. (4/3881)

Prostate-specific antigen (PSA) is a serine protease which may play a role in a variety of cancer types, including breast cancer. In the present study, we evaluated whether the level of PSA in breast tumour cytosol could be associated with prognosis in primary breast cancer, or with response to tamoxifen therapy in recurrent disease. PSA levels were determined by enzyme-linked immunosorbent assay (ELISA) in breast tumour cytosols, and were correlated with prognosis in 1516 patients with primary breast cancer and with response to first-line tamoxifen therapy in 434 patients with recurrent disease. Relating the levels of PSA with classical prognostic factors, low levels were more often found in larger tumours, tumours of older and post-menopausal patients, and in steroid hormone receptor-negative tumours. There was no significant association between the levels of PSA with grade of differentiation or the number of involved lymph nodes. In patients with primary breast cancer, PSA was not significantly related to the rate of relapse, and a positive association of PSA with an improved survival could be attributed to its relationship to age. In patients with recurrent breast cancer, a high level of PSA was significantly related to a poor response to tamoxifen therapy, and a short progression-free and overall survival after start of treatment for recurrent disease. In Cox multivariate analyses for response to therapy and for (progression-free) survival, corrected for age/menopausal status, disease-free interval, site of relapse and steroid hormone receptor status, PSA was an independent variable of poor prognosis. It is concluded that the level of PSA in cytosols of primary breast tumours might be a marker to select breast cancer patients who may benefit from systemic tamoxifen therapy.  (+info)

Menopausal status and distensibility of the common carotid artery. (5/3881)

Although several studies have shown that exogenous estrogens have beneficial effects on arterial characteristics, the effect of endogenous estrogen on the vascular system is still unknown. In this study, distensibility, an indicator of arterial elasticity, of the common carotid artery was compared in pre- and postmenopausal women. The study comprised 93 premenopausal and 93 postmenopausal women of similar age (range, 43 to 55 years). Women were selected from respondents to a mailed questionnaire about the menopause, which was sent to all women aged 40 to 60 years in the Dutch town of Zoetermeer (n=12 675). Postmenopausal women who were at least 3 years past natural menopause or whose menses had stopped naturally before age 48, were age-matched with premenopausal women with regular menses and without menopausal complaints. The selection aimed at maximizing the contrast in estrogen status between pre- and postmenopausal women of the same age. Distensibility of the carotid artery was measured noninvasively with B-mode ultrasound and a vessel wall movement detector system. Arterial distensibility is expressed as the change in arterial diameter (distension, DeltaD) with the cardiac cycle, adjusted for lumen diameter, pulse pressure, and mean arterial blood pressure. Compared with premenopausal women, postmenopausal women had significantly lower arterial distension (DeltaD 370.5 microm [SE 9.5] versus 397.3 microm [SE 9.6]). These results suggest that the distensibility of the common carotid artery is negatively affected by natural menopause in presumed healthy women.  (+info)

Health aspects of partially defatted flaxseed, including effects on serum lipids, oxidative measures, and ex vivo androgen and progestin activity: a controlled crossover trial. (6/3881)

BACKGROUND: Currently there is considerable interest in the potential health benefits of oil seeds, such as soy and flaxseed, especially in relation to cardiovascular disease and cancer. OBJECTIVE: We therefore evaluated health aspects of partially defatted flaxseed in relation to serum lipids, indicators of oxidative stress, and ex vivo sex hormone activities. DESIGN: Twenty-nine hyperlipidemic subjects (22 men and 7 postmenopausal women) completed two 3-wk treatment periods in a randomized, crossover trial. Subjects were given muffins that contributed approximately 20 g fiber/d from either flaxseed (approximately 50 g partially defatted flaxseed/d) or wheat bran (control) while they consumed self-selected National Cholesterol Education Program Step II diets. Both muffins had similar macronutrient profiles. Treatment phases were separated by > or = 2 wk. RESULTS: Partially defatted flaxseed reduced total cholesterol (4.6+/-1.2%; P = 0.001), LDL cholesterol (7.6+/-1.8%; P < 0.001), apolipoprotein B (5.4+/-1.4%; P = 0.001), and apolipoprotein A-I (5.8+/-1.9%; P = 0.005), but had no effect on serum lipoprotein ratios at week 3 compared with the control. There were no significant effects on serum HDL cholesterol, serum protein carbonyl content, or ex vivo androgen or progestin activity after either treatment. Unexpectedly, serum protein thiol groups were significantly lower (10.8+/-3.6%; P = 0.007) at week 3 after the flaxseed treatment than after the control, suggesting increased oxidation. CONCLUSIONS: These data indicate that partially defatted flaxseed is effective in lowering LDL cholesterol. No effects on lipoprotein ratios, ex vivo serum androgen or progestin activity, or protein carbonyl content were observed. The significance of increased oxidation of protein thiol groups with flaxseed consumption requires further investigation.  (+info)

Hormone replacement therapy increases isometric muscle strength of adductor pollicis in post-menopausal women. (7/3881)

A randomized open trial of hormone replacement therapy was used to assess changes in adductor pollicis muscle strength during 6-12 months of treatment with Prempak C 0.625(R) in comparison with an untreated control group. Muscle strength (maximal voluntary force; MVF), muscle cross-sectional area and bone mineral density were measured. Women entering the trial had oestrogen levels below 150 pmol.l-1, confirming their post-menopausal hormonal status. In the treated group, MVF increased by 12.4+/-1.0% (mean+/-S.E.M.) of initial MVF over the duration of treatment, while it declined slightly (2.9+/-0.9%) in the control group. This increase in strength could not be explained by an increase in muscle bulk, there being no significant increase in cross-sectional area during the study. Those subjects who were weakest at enrolment showed the greatest increases in muscle strength after treatment. Bone mineral density in total hip, Ward's triangle and total spine increased in the treated group, in agreement with previous studies. There was no correlation between the individual increases in bone mineral density and those in MVF.  (+info)

Meta-analysis: dietary fat intake, serum estrogen levels, and the risk of breast cancer. (8/3881)

BACKGROUND: There is compelling evidence that estrogens influence breast cancer risk. Since the mid-1980s, dietary fat intervention studies have been conducted to investigate the effect of fat intake on endogenous estrogen levels. To further our understanding of the possible relationship between dietary fat and breast cancer, we conducted a meta-analysis of dietary fat intervention studies that investigated serum estradiol levels, and we reviewed the nature of the evidence provided by prospective analytic studies of fat consumption and breast cancer risk. METHODS: A computerized search of the English language literature on estrogen/estradiol and dietary fat intervention studies published from January 1966 through June 1998 was conducted using the MEDLINE database. Pooled estimates were derived from the change in estradiol levels associated with fat reduction from 13 studies. Analyses were conducted separately for premenopausal and postmenopausal women and in both groups combined. RESULTS AND CONCLUSIONS: Statistically significant reductions in serum estradiol levels of -7.4% (95% confidence interval [CI] = -11.7% to -2.9%) among premenopausal women and -23.0% (95% CI = -27.7% to -18.1%) among postmenopausal women were observed, with an overall -13.4% (95% CI = -16.6% to -10.1%) reduction observed. The greatest reductions occurred in two studies in which dietary fat was reduced to 10%-12% of calories compared with 18%-25% of calories in the other studies. A statistically significant reduction in estradiol levels of -6.6% (95% CI = -10.3% to -2.7%) remained after exclusion of these two studies. Review of prospective analytic epidemiologic studies that allowed for dietary measurement error suggests that the possibility that reducing fat consumption below 20% of calories will reduce breast cancer risk cannot be excluded. IMPLICATIONS: Dietary fat reduction can result in a lowering of serum estradiol levels and such dietary modification may still offer an approach to breast cancer prevention.  (+info)

*Menopause

... menopause or postmenopause can be identified by a blood test showing a very high FSH level. Thus postmenopause is the time in a ... PostmenopauseEdit. The term "postmenopausal" describes women who have not experienced any menstrual flow for a minimum of 12 ... The reason for this delay in declaring postmenopause is because periods are usually erratic at this time of life. Therefore, a ... The menopausal transition, and postmenopause itself, is a natural change, not usually a disease state or a disorder. The main ...

*Hormone replacement therapy

... postmenopause'.[4] Premature menopause can occur if the ovaries are surgically removed, as can be done to treat ovarian or ... There may be an increase in heart disease if HRT is given twenty years post-menopause.[24] There is, however, no actual ... Effects of hormone replacement therapy on sexual psychophysiology and behavior in postmenopause. Journal of Women's Health and ...

*Femarelle

Poluzzi E, et al Phytoestrogens in postmenopause: the state of the art from a chemical, pharmacological and regulatory ...

*Anorgasmia

The problem is greater in women who are post-menopause. The condition is sometimes classified as a psychiatric disorder. ...

*Insomnia

... especially in and post-menopause.[28][49] ...

*Menopause

Thus postmenopause is the time in a woman's life that takes place after her last period or, more accurately, after the point ... In women without a uterus, menopause or postmenopause can be identified by a blood test showing a very high FSH level. ... The reason for this delay in declaring postmenopause is because periods are usually erratic at this time of life. Therefore, a ... A period-like flow during postmenopause, even spotting, may be a sign of endometrial cancer. Perimenopause is a natural stage ...

*Hormone replacement therapy

... also known as perimenopause and postmenopause. Each stage is marked by changes in hormonal patterns, which can induce ... Effects of hormone replacement therapy on sexual psychophysiology and behavior in postmenopause. Journal of Women's Health and ...

*Hormone replacement therapy (menopause)

Menopause can be divided into early and late transition periods, also known as perimenopause and postmenopause. Each stage is ... Sarrel, P.M. (2000). Effects of hormone replacement therapy on sexual psychophysiology and behavior in postmenopause. Journal ...

*Estradiol

Clinical recovery from depression postpartum, perimenopause, and postmenopause was shown to be effective after levels of ...

*Allenolic acid

The Menopause and Postmenopause: The Proceedings of an International Symposium held in Rome, June 1979. Springer Science & ...

*Dimethisterone

430-. ISBN 978-1-4757-2085-3. Rodolfo Paoletti; N. Pasetto; J.L. Ambrus (6 December 2012). The Menopause and Postmenopause: The ...

*Android fat distribution

An android fat distribution becomes more common post-menopause, where oestrogen is at its lowest levels. Older men show android ...

*Insomnia

... especially in and post-menopause. Changes in sex hormones in both men and women as they age may account in part for increased ...

*Night sweats

... and postmenopause life stages". Archives of women's mental health. 10 (6): 247-257. doi:10.1007/s00737-007-0209-5. Retrieved 5 ...

*Postmenopausal confusion

... estrogen levels fluctuate during the menstrual cycle but reach a steady decline and then remain at low levels postmenopause. ... widely found that this treatment must be administered near to the onset of menopause as opposed to several years postmenopause ...

*Estradiol

Clinical recovery from depression postpartum, perimenopause, and postmenopause was shown to be effective after levels of ...

*Phytoestrogens

... the nutritional role of phytoestrogens in the regulation of cholesterol and the maintenance of proper bone density post-menopause ...

*Endometriosis

... can affect any female, from premenarche to postmenopause, regardless of race or ethnicity or whether or not they ...

*Estradiol

Clinical recovery from depression postpartum, perimenopause, and postmenopause was shown to be effective after levels of ...

*Atrophic vaginitis

... and increasingly so in post-menopause. However this condition can occur in other circumstances that result in decreased ...

*Estrogen

Clinical recovery from postpartum, perimenopause, and postmenopause depression has been shown to be effective after levels of ...

*Iron

The current EAR for iron for women ages 14-18 is 7.9 mg/day, 8.1 for ages 19-50 and 5.0 thereafter (post menopause). For men ...

*Triphenylmethylethylene

189-. ISBN 978-90-313-6143-4. Obiorah I, Jordan VC (2013). "Scientific rationale for postmenopause delay in the use of ...

*Catamenial epilepsy

Women progressing through peri- and post-menopause using HRT may be in greater need of anticonvulsant medication monitoring to ...

*Ovarian fibroma

They tend to occur mostly during perimenopause and postmenopause, the median age having been reported to be about 52 years, and ...

*Soy protein

The panel also found soy isoflavones do not reduce postmenopause "hot flashes" in women, nor do isoflavones lower risk of ...
WASHINGTON, D.C. - Reported mid-life increase in body mass index (BMI) may lead to substantially higher risk of postmenopausal breast cancer, according to results of a prospective cohort study presented at the American Association for Cancer Research 101st Annual Meeting 2010, held here, April 17-21.. In previous studies, excess weight has been linked with increased risk of postmenopausal breast cancer. Scientists have speculated that in postmenopausal women, estrogen produced in adipose tissue, or body fat, may promote breast cell proliferation. Relatively few studies have looked specifically at increase in BMI and its timing in relation to postmenopausal breast cancer risk, which this study investigated.. The researchers analyzed information from 72,007 women in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial cohort, who were 55 to 74 years old at study entry. The analysis included 3,677 cases of postmenopausal breast cancer, which makes this one of the larger studies of its ...
This is to date the only study that we are aware of investigating the association of change in SS and breast cancer risk. Our data suggests that a unit increase in UK SS (eg, 12-14) every 10 years between the 20s and postmenopausal age increases the risk of postmenopausal breast cancer by 33%. We estimated an increase in 5-year absolute risk of postmenopausal breast cancer from 1 in 61 to 1 in 51 with each unit increase in SS per 10 years. Reductions in SS decreased the risk of breast cancer (figure 2) though it should be noted that for 76% of the women in this study, SS increased over their adult lifetime. These findings may provide women with a simple and easy to understand message given that SS has been found to be a reliable measure for changes in waist circumference and one that women may relate and understand better in comparison to other adiposity measures such as BMI.5. The major strengths of this study are its prospective cohort design, sample size, comprehensive follow-up through ...
PRIMARY OBJECTIVES:. I. Compare the effect of lower and intermittent doses of letrozole to standard letrozole therapy on estrogen suppression in postmenopausal women at high risk for developing breast cancer.. SECONDARY OBJECTIVES:. I. Comparison of the effect of lower and intermittent doses of letrozole to standard therapy on signs and symptoms of estrogen deficiency, including menopausal symptoms, serum lipid profile, and serum marker of bone turnover.. II. Comparison of the effect of lower and intermittent doses of letrozole to standard therapy on nuclear chromatin abnormality of breast epithelial cells collected by random periareolar fine needle aspiration (RPFNA).. TERTIARY OBJECTIVES:. I. Determine the prevalence of breast cancer stem cells in the fine needle breast aspirates and explore the potential intervention effect on the prevalence of breast cancer stem cells.. OUTLINE: Patients are randomized to 1 of 4 treatment arms.. ARM I: Patients receive 2.5 mg of letrozole orally (PO) thrice ...
In this prospective cohort study of Korean postmenopausal women, it is of interest to note that BMI was an independent predictor of mortality for total stroke, particularly for hemorrhagic stroke. The association for death due to the total and hemorrhagic stroke mortality was stronger among women who experienced early menopause but not among those who experienced late menopause. Meanwhile, among total postmenopausal women, BMI was not associated with ischemic stroke mortality, whereas among smoking postmenopausal women, the obese women (BMI ≥27.5 kg/m2) had a significantly high risk of ischemic stroke mortality (adjusted HR, 7.21) in our data.. Although being overweight, particularly obesity, is known to be a risk factor for the incidence or death of cardiovascular disease,16 study results on the relationship between obesity and stroke mortality in Asian populations are not always consistent.3,4,17⇓⇓ Some studies have also noted a substantially increased risk of total and ischemic strokes ...
Evidence continues to mount regarding the health impact of trans fats in ones diet. According to a large new study, trans fats increase the risk of ischemic strokes in postmenopausal women. In addition, the report noted that the risk could be decreased with aspirin (An ischemic stroke is one due to a blockage of an artery, which results in lack of blood supply to a portion of the brain.) The study was published online on March 1 in the Annals of Neurology.. The researchers derived their data from 87,025 generally healthy postmenopausal women aged 50 to 79 years who were enrolled in the Womens Health Initiative Observational Study from 1994 through 1998. The investigators assessed the womens diets via a self-administered food frequency questionnaire. The women were queried regarding their frequency of intake of fats in meat and dairy products, fats used in cooking, added fats, and reduced-fat foods during the previous three months. The women were evaluated at enrollment and at a follow-up ...
The purpose of this study is to evaluate safety parameters of anastrozole with regard to its potential effects on postmenopausal bone loss and on lipid profiles. This trial is conducted to investigate the effects of risedronate on BMD and on bone metabolism in postmenopausal women using anastrozole as adjuvant therapy for hormone-receptor-positive early breast cancer and who are high or moderate risk of fragility fracture. It is also conducted to determine the effects of anastrozole on bone mineral density (BMD) and on bone metabolism in women at low risk of fragility fracture ...
Results: Pre- and post-menopausal women had a median age of 35 (31 to 42) and 57 (52 to 68); body mass index 25 (24 to 28) and 27 (23 to 29), CrCl 86 (58 to 112) and 76 (65 to 104) mL/min, respectively. We enrolled 10 African American and 2 white pre-menopausal women; and 5 African American and 1 Hispanic post-menopausal women. After first dose, blood plasma exposure was similar, but genital tract exposure was increased in post-menopausal women resulting in an increased genital tract : blood plasma ratio. At steady state, post-menopausal women had greater exposure in both blood plasma (p = 0.02) and genital tract (p = 0.01), resulting in similar genital tract : blood plasma ratios. C24h was greater in blood plasma (p = 0.04) and genital tract (p = 0.01) in post-menopausal women at steady state. In post-menopausal women, blood plasma AUC and blood plasma C24h exceed standard pharmacokinetic parameters by 160% and 125%, respectively. ...
Results from a Phase III clinical trial have shown that combining two existing cancer drugs to treat post-menopausal women with advanced breast cancer resistant to hormonal therapy significantly improves outcome. The BOLERO 2 trial showed that women treated with a combination of everolimus and exemestane had an improved progression-free survival of nearly seven months compared to women who were treated only with exemestane. This research will be presented on Sept. 26 at the 2011 European Multidisciplinary Cancer Congress.
The depletion of estrogen and progesterone in postmenopausal women is associated with increased risk for several disorders in the cardiovascular, skeletal and nervous system. To reduce this risk, hormone therapy containing estrogens and a synthetic progestagen has been used but with little success. For example, the Womens Health Initiative clinical trial showed that hormone therapy was associated with reduced incidence of hip fractures associated with osteoporosis but unexpectedly increased incidences of both stroke and dementia. The disparities between basic research studies that demonstrate neuroprotective effects of estrogen and progesterone and recent clinical findings that report adverse neural effects of hormone therapy indicate the need for a more complete understanding of estrogens and progesterone interactions in brain and other tissues. One important issue that is not well understood is how neural effects of estrogens are affected by progestagens. Recent experimental evidence shows ...
The investigators are hypothesizing that decreasing estrogen levels will cause serum DKK1 to peak, then decrease gradually as estrogens reach a new lowe
Genome-wide association studies have identified several genomic regions that are associated with breast cancer risk, but these provide an explanation for only a small fraction of familial breast cancer aggregation. Genotype by environment interactions may contribute further to such explanation, and may help to refine the genomic regions of interest. We examined genotypes for 4,988 SNPs, selected from recent genome-wide studies, and four randomized hormonal and dietary interventions among 2,166 women who developed invasive breast cancer during the intervention phase of the Womens Health Initiative (WHI) clinical trial (1993 to 2005), and one-to-one matched controls. These SNPs derive from 3,224 genomic regions having pairwise squared correlation (r2) between adjacent regions less than 0.2. Breast cancer and SNP associations were identified using a test statistic that combined evidence of overall association with evidence for SNPs by intervention interaction. The combined main effect and interaction
Data from the Womens Health Initiative Observational Study show that higher than normal insulin levels are an independent risk factor for breast cancer.
TY - JOUR. T1 - Reproductive hormone exposure timing and ischemic heart disease. T2 - Complicated answers to a simple question. AU - Bairey Merz, C. Noel. AU - Shufelt, Chrisandra. AU - Johnson, B. Delia. AU - Azziz, Ricardo. AU - Braunstein, Glenn D.. PY - 2010/4/1. Y1 - 2010/4/1. N2 - The current literature, combined with improved methodology in the WISE study, suggests that there is a beneficial relation between HT use and IHD in peri- and early postmenopausal women. Our results are also consistent with recent clinical trials that have failed to show benefit of HT initiation in older postmenopausal women, either for angiographic coronary disease or cardiac events. Overall, our data suggest that the anti-atherosclerotic effect of HT, if present, may be age-dependent and primarily evident in relatively younger peri- and early postmenopausal women.. AB - The current literature, combined with improved methodology in the WISE study, suggests that there is a beneficial relation between HT use and ...
Evidence from observational studies has suggested the use of oestrogen alone, and oestrogen and progestin therapy (hormone replacement therapy, [HRT]) for postmenopausal women with CHD on the basis of a potential risk reduction in the order of 40% for recurrent events.1, 2. The HERS is the first large scale, randomised controlled trial in which the effects of HRT on CHD mortality and morbidity have been examined in postmenopausal women with established CHD. The findings of no difference in CHD mortality and non-fatal cardiac events, and increases in venous thrombosis among patients in the treated group have led to much discussion in the cardiovascular community.. Past observational studies may have been hampered by selection bias. For example, women who choose to use HRT may already be proactive in managing their health through other behaviours such as exercise and diet, and positive outcomes may have been confounded by this bias.. The increase in venous thrombosis in the treated group is an ...
The results of this randomized clinical trial suggest that exercise can lower levels of circulating estrogens and increase levels of SHBG in previously sedentary, overweight/obese postmenopausal women. The study had excellent retention and adherence, which decreases the chance of biased results and increases study power. The data indicate that loss of body fat in conjunction with exercise is needed to achieve these hormone changes but that exercise need not be of vigorous intensity. This is the first randomized clinical trial to test an exercise intervention on serum estrogens in postmenopausal women, and the results support our hypothesized mechanism that exercise could lower breast cancer risk in postmenopausal women by reducing body fat and ultimately circulating estrogen concentrations. Our observations of a 13.7 and 16.7% decrease in estradiol and free estradiol among exercisers who lost ,2% of body fat are likely to be clinically significant. In comparison, low-fat dietary trials (18-25% ...
Results from this study suggest that the reduced risk of postmenopausal breast cancer associated with frequent episodes strenuous physical activity at 14-22 years of age may be greatest in women who were heaviest within the same time period or who, over the adult years, either lost weight or gained only modest amounts. Among women who were heaviest at age 18, risk of postmenopausal breast cancer was reduced by about 50% in those who exercised frequently.. More pronounced were results obtained from the model examining the joint effects of early-life physical activity and weight change between age 18 and 5 years before interview. Risk of postmenopausal breast cancer was reduced by about 80% among women who were active on a very frequent basis as young adults and who had lost weight between age 18 and 5 years before interview, independent of initial weight. However, given the small sample size of this subgroup, this estimate is unstable. Interestingly, among women with little lifetime weight gain ...
Studies have suggested that hormones may play a potential role in melanoma carcinogenesis. Is hormone replacement therapy associated with an increased risk of melanoma in post-menopausal women?Human Reproduction...
We examined the relation of GSTM1, GSTT1, and GSTP1 genotypes and breast cancer risk in a population-based, case-control study of African-American and white women in North Carolina. GSTM1, GSTT1, and GSTP1 genotypes were not associated with breast cancer risk in African-American or white women, or among pre- or postmenopausal women. Two previous studies reported no overall association between GSTM1 genotype and breast cancer risk (19 , 20) . Helzlsouer et al. (9) and Charrier et al. (21) reported positive associations for the GSTM1 null genotype among postmenopausal but not premenopausal women, whereas Ambrosone et al. (22) reported a positive association for GSTM1 null genotype among younger postmenopausal women. In contrast, Garcia-Closas et al. (23) reported no association for GSTM1 null genotype in pre- or postmenopausal women. Helzlsouer et al. (9) reported no association for GSTT1 null genotype and breast cancer in pre- or postmenopausal women, whereas Garcia-Closas et al. (23) observed an ...
Use words for any number that begins a sentence, title, subtitle, or heading. However, it may be better to reword the sentence so that it does not begin with a number.Three hundred twenty-eight men and 126 women were included in the study. Better: The study population comprised 328 men and 126 women. Participants: Seventy-two thousand three hundred thirty-seven postmenopausal women aged 34 to 77 years. Better: Participants: A total of 72 337 postmenopausal women aged 34 to 77 years. Three patients were identified; 2 had hypertension and 1 had diabetes. Numerals may be used in sentences that begin
Women with the highest bone mass are at much greater risk of postmenopausal breast cancer than those with lower bone mass, according to the results of a long-term epidemiological study supported by the National Institutes of Health
Fat near heart in women can increase risk of heart attacks and other diseases in women. The threat of such disease increases even further during postmenopausal phase. Apart from heart disease, fat is also responsible for causing increase in cholesterol levels in women. Let us understand how fat near heart is a risk factor for postmenopausal women and how to reduce it.
Health,...Postmenopausal women without symptoms of cardiovascular problems who h...Resting 12-lead electrocardiogram (ECG) abnormalities are independentl...Pablo Denes M.D. of the Feinberg School of Medicine Northwestern Un...The sample analyzed included 14749 postmenopausal asymptomatic women ...,Both,minor,and,major,ECG,abnormalities,linked,with,increased,risk,of,cardiovascular,events,in,women,medicine,medical news today,latest medical news,medical newsletters,current medical news,latest medicine news
ROCHESTER, Minn. -- A daily dose of crushed flaxseed halved hot flashes in postmenopausal women who did not want to take estrogen, according to a pilot study.
A study that examined the prevalence and correlates of vaginal estrogenization in postmenopausal women in the United States found that in every age group, vaginal estrogenization was _______________ among postmenopausal nonusers of hormone therapy in the 2005 to 2006 cohort, compared with historical clinical data. ...
Results of a trial reveal breast cancer incidence among postmenopausal women at high risk for developing the disease was significantly reduced by the antihormone therapy anastrozole.
Weight loss of 5 percent or more, combined with vitamin D3 supplementation, is associated with significant reductions in interleukin-6 in postmenopausal women
Amgen Inc. (Nasdaq: AMGN) announced that the U. S. Food and Drug Administration (FDA) has approved Prolia(TM) (denosumab) for the treatment of postmenopausal women
Postmenopausal women shouldnt take low-dose supplements of vitamin D and calcium in hopes of preventing broken bones, a government panel recommended on Tuesday. The U.S.
They get enough form into its download treatment of the postmenopausal woman basic and clinical aspects. I principally bear to discover the esse of Bowles. All that maximizes therefore, each often as the download treatment of the to be is last, has the fine esse itself.
Blood, Bones, Heart and Health: Preventing Chronic Disease in Post-Menopausal Women.. Includes guidelines for preventing osteoporosis and improving cardiovascular health. The importance of treating inflammation and infection as well as an Annual Herbal Prescription and daily dietary and lifestyle suggestions will be covered.. ...
This reduction in breast cancer risk is similar to that already reported in 2 other studies, both of which were presented in December 2009 at the San Antonio Breast Cancer Symposium. One was an analysis of more than 150,000 postmenopausal women participating in several Womens Health Initiative studies, which found that bisphosphonate use reduced the risk for invasive breast cancer by 32%. The other involved an analysis of 4575 postmenopausal women in Israel, which found a 34% reduction ...
A new study published in Cancer Epidemiology, Biomarkers,& Prevention concluded that the taller a postmenopausal woman is, the greater her risk for developing cancer. In this study of over 20,900 postmenopausal women the association of height was linked to breast, colon, endometrium, kidney, ovary, rectum, thyroid, multiple myeloma, and melanoma and the associations did not change when adjusting for factors known to influence these cancers. . The researchers said "We were suprised at the number of cancer sites than were positively associated with height. In this data set, more cancers are associated with height than were associated with body mass iindex (BMI)." They further said "Ultimately, cancer is a result of processes having to do with growth, so it makes sense that hormones or other growth factors that influence height may also influence cancer risk.". Postmenopausal women in the study were between ages 50 and 79 and data was collected between 1993 and 1998. When entering the larger study ...
Its no surprise that diet, nutrition and exercise are regarded as the most important factors in not only reducing diabetes, but controlling it.
A new study has found that weight has the biggest influence on levels of the sex hormone oestrogen, which is known to fuel some types of postmenopausal breast cancer.
Soy supplements provided neither positive or negative changes in overall mental abilities in postmenopausal women, U.S. researchers said.
You may see home med lists include prasterone (Intrarosa, (in-trah-ROH-sah), a new Rx to treat intercourse pain in postmenopausal women.... Learn more with Pharmacists Letter Hospital.
Clinical Trials - clinicaltrials.gov The purpose of this study is to determine the safety, tolerability, and effectiveness of the amino acid L-isoleucine in the...
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Womens and Childrens Health, International Maternal and Child Health (IMCH). (Lindmark) ...
Life Enhancement Products, an innovative manufacturer of nutritional supplements with unique formulations for memory enhancement, blood sugar maintenance, thyroid support, weight control, gastrointestinal support, and more.
Sigma-Aldrich offers abstracts and full-text articles by [Patricia Sarrión, Leonardo Mellibovsky, Roser Urreizti, Sergi Civit, Neus Cols, Natàlia García-Giralt, Guy Yoskovitz, Alvaro Aranguren, Jorge Malouf, Silvana Di Gregorio, Luís Del Río, Roberto Güerri, Xavier Nogués, Adolfo Díez-Pérez, Daniel Grinberg, Susana Balcells].
Learn more about Postmenopausal Bleeding at Colleton Medical Center DefinitionCausesRisk FactorsSymptomsDiagnosisTreatmentPreventionrevision ...
Care guide for Postmenopausal Bleeding. Includes: possible causes, signs and symptoms, standard treatment options and means of care and support.
Learn more about Postmenopausal Bleeding at TriStar Centennial Parthenon Pavilion DefinitionCausesRisk FactorsSymptomsDiagnosisTreatmentPreventionrevision ...
With the most common cause of postmenopausal bleeding being vaginal or endometrial atrophy, there is always a concern of the presence of endometrial cancer, as 10% of women with PMB have the disease.
Looking for online definition of postmenopause in the Medical Dictionary? postmenopause explanation free. What is postmenopause? Meaning of postmenopause medical term. What does postmenopause mean?
Complex ovarian cysts in postmenopausal women are not associated with ovarian cancer risk factors: preliminary data from the Prostate, Lung, Colon, and Ovarian Cancer Screening Trial
TY - JOUR. T1 - Metabolic syndrome and postmenopausal breast cancer in the ORDET cohort. T2 - A nested case-control study. AU - Agnoli, C.. AU - Berrino, F.. AU - Abagnato, C. A.. AU - Muti, P.. AU - Panico, S.. AU - Crosignani, P.. AU - Krogh, V.. PY - 2010/1. Y1 - 2010/1. N2 - Background and aims: The increase in breast cancer incidence over recent decades has been accompanied by an increase in the frequency of metabolic syndrome. Several studies suggest that breast cancer risk is associated with the components of metabolic syndrome (high serum glucose and triglycerides, low HDL-cholesterol, high blood pressure, and abdominal obesity), but no prospective study has investigated risk in relation to the presence of explicitly defined metabolic syndrome. We investigated associations between metabolic syndrome, its components, and breast cancer risk in a nested case-control study on postmenopausal women of the ORDET cohort. Methods and results: After a median follow-up of 13.5 years, 163 women ...
Postmenopause: Find the most comprehensive real-world symptom and treatment data on postmenopause at PatientsLikeMe. 84 patients with postmenopause experience fatigue, depressed mood, pain, anxious mood, and insomnia and use Buprenorphine patch, Hydrocodone-Acetaminophen, Hydroxyzine, Oxycodone-acetaminophen, and Acetaminophen (Paracetamol) to treat their postmenopause and its symptoms.
Women with benign proliferative breast disease (BPBD) are at increased risk for developing breast cancer. Evidence suggests that accumulation of adipose tissue can influence breast cancer development via hyperinsulinemia, increased estrogen, and/or inflammation. However, there are limited data investigating these pathways with respect to risk of BPBD. We evaluated serologic markers from these pathways in a case-control study of postmenopausal women nested within the Womens Health Initiative Clinical Trial. Cases were the 667 women who developed BPBD during follow-up, and they were matched to 1,321 controls. Levels of insulin, estradiol, C-reactive protein (CRP), and adiponectin were measured in fasting serum collected at baseline. Conditional logistic regression models were used to estimate ORs for the association of each factor with BPBD risk. Among nonusers of hormone therapy, fasting serum insulin was associated with a statistically significant increase in risk of BPBD (OR for highest vs. ...
TY - JOUR. T1 - Twinship and risk of postmenopausal breast cancer. AU - Cerhan, James R.. AU - Kushi, Lawrence H.. AU - Olson, Janet E.. AU - Rich, Stephen S.. AU - Zheng, Wei. AU - Folsom, Aaron R.. AU - Sellers, Thomas A.. PY - 2000/2/2. Y1 - 2000/2/2. N2 - Background: Intrauterine exposure to high levels of endogenous estrogens has been hypothesized to increase the risk of breast cancer. Because estrogens and other pregnancy hormones are substantially elevated in twin pregnancies, and possibly more so in dizygotic twin pregnancies, we evaluated the association between aspects of twin membership (i.e., belonging to a twin pair) and the risk of breast cancer. Methods: In a cohort of 29 197 postmenopausal Iowa women with no prior diagnosis of cancer (except for nonmelanoma skin cancer), breast cancer risk factors were determined by use of a mailed questionnaire in 1986 (baseline); twin membership, sex of the twin, and zygosity were determined by use of a follow-up questionnaire in 1992. Results: ...
Tager, F.A., McKinley, P.S., Schnabel, F.R. et al. Breast Cancer Res Treat (2011) 126: 271. https://doi.org/10.1007/s10549-009-0684- ...
Kidney cancer incidence is increasing globally. Reasons for this rise are unclear but could relate to obesity and hypertension. We analyzed longitudinal relationships between hypertension and obesity and kidney cancer incidence in 156 774 participants of the Womens Health Initiative clinical trials and observational studies over 10.8 years. In addition, we examined the effect of blood pressure (BP) on kidney cancer deaths for over 25 years among the 353 340 men screened for the Multiple Risk Factor Intervention Trial (MRFIT). In the Womens Health Initiative, systolic BP (SBP) was categorized in 6 groups from ,120 to ,160 mm Hg, and body mass index was categorized using standard criteria. In age-adjusted analyses, kidney cancer risk increased across SBP categories (P value for trend ,0.0001) and body mass index categories (P value for trend ,0.0001). In adjusted Cox proportional hazards models, both SBP levels and body mass index were predictors of kidney cancer. In the MRFIT sample, there were ...
TY - JOUR. T1 - Pre-menopausal and post-menopausal depressed women. AU - Roy, Alec. AU - Linnoila, Markku. AU - Jimerson, David C.. AU - Gold, Philip. AU - Pickar, David. PY - 1986. Y1 - 1986. N2 - In a consecutive series of 28 depressed women, pre-menopausal (n = 13) and post-menopausal (n = 15) patients were compared. Post-menopausal women had significantly higher levels of plasma norepinephrine, plasma 3-methoxy-4-hydroxyphenylglycol, post-dexamethasone plasma cortisol, cerebrospinal fluid 3-methoxy-4-hydroxyphenylglycol and corticotropin-releasing hormone. However, when biologic measures were adjusted for age by analyses of covariance there were no significant differences. Pre-menopausal women had had significantly more life events before the onset of depression than post-menopausal women. The implications of these findings are discussed.. AB - In a consecutive series of 28 depressed women, pre-menopausal (n = 13) and post-menopausal (n = 15) patients were compared. Post-menopausal women had ...
Background: The potential benefits of hormone therapy (HT) in treating depressed postmenopausal women are controversial, and data on depression (re)emergence in the context of HT discontinuation are lacking.. Objective: To determine whether HT is associated with a modified risk of new-onset depressive symptoms in elderly women.. Method: Current depressive symptomatology was evaluated in 4,069 community-dwelling postmenopausal women aged 65 years and over who were randomly recruited from 3 French cities between 1999 and 2001. Depressive symptomatology was assessed using the Center for Epidemiologic Studies-Depression Scale at baseline and as part of the 2- and 4-year follow-up.. Results: Over the follow-up period, multivariate logistic regression analyses adjusted for sociodemographic variables, measures of physical health, and cognitive impairment failed to find a significant association between HT at baseline and the incidence of depressive symptoms. However further analysis indicated an ...
This study investigates whether the incidence of new-onset diabetes mellitus (DM) is associated with statin use among postmenopausal women participating in the Womens Health Initiative (WHI).. [swfobj src="http://www.asociaciondecardiologiadeelsalvador.com/wp-content/uploads/2012/02/statins.swf" width="590px" height="480px ...
TY - JOUR. T1 - Insulin, insulin-like growth factor-I, and risk of breast cancer in postmenopausal women. AU - Gunter, Marc J.. AU - Hoover, Donald R.. AU - Yu, Herbert. AU - Wassertheil-Smoller, Sylvia. AU - Rohan, Thomas E.. AU - Manson, Joann E.. AU - Li, Jixin. AU - Ho, Gloria Y F. AU - Xue, Xiaonan (Nan). AU - Anderson, Garnet L.. AU - Kaplan, Robert C.. AU - Harris, Tiffany G.. AU - Howard, Barbara V.. AU - Wylie-Rosett, Judith. AU - Burk, Robert D.. AU - Strickler, Howard. PY - 2009/1. Y1 - 2009/1. N2 - Background: The positive association between obesity and postmenopausal breast cancer has been attributed, in part, to the fact that estrogen, a risk factor for breast cancer, is synthesized in adipose tissue. Obesity is also associated with high levels of insulin, a known mitogen. However, no prospective studies have directly assessed associations between circulating levels of insulin and/or insulin-like growth factor (IGF)-I, a related hormone, and the risk of breast cancer independent ...
Mathematical methods exist to determine the fractions of sex hormones bound to albumin, bound to sex hormone binding globulin (SHBG), or unbound, using total hormone concentration and SHBG concentration. We used data from eight prospective studies of postmenopausal women to assess the validity of these estimates for fractions of estradiol (E2) and to investigate the impact of using calculated values in breast cancer relative risk (RR) models. Comparisons were made between measured and calculated concentrations of free and non-SHBG-bound E2 in four studies. Relationships between the hormone fractions were investigated and a sensitivity analysis of the calculation performed. Breast cancer RRs were estimated using conditional logistic regression by quintiles of free E2. There is a high correlation (r | 0.91) between calculated and measured values of both free and non-SHBG-bound E2. The calculation is highly sensitive to total hormone concentration but is relatively insensitive to SHBG concentration. In
TY - JOUR. T1 - Hot flashes in postmenopausal women treated for breast carcinoma. T2 - Prevalence, severity, correlates, management, and relation to quality of life. AU - Carpenter, Janet S.. AU - Andrykowski, Michael A.. AU - Cordova, Matthew. AU - Cunningham, Lauren. AU - Studts, Jamie. AU - McGrath, Patrick. AU - Kenady, Daniel. AU - Sloan, David. AU - Munn, Rita. PY - 1998/5/1. Y1 - 1998/5/1. N2 - BACKGROUND. Research on hot flashes (HFs) after the diagnosis and treatment of breast carcinoma (BC) is scarce. To our knowledge, this research represents the second study of HF prevalence and severity in women with BC and the first study of 1) correlates of HF prevalence and severity, 2) use of HF management strategies, and 3) the relation between HFs and quality of life (QOL) among women with BC. METHODS. Eligible women (n = 136) participated in structured telephone interviews. RESULTS. Of the 114 postmenopausal women interviewed, 65% reported HFs, with 59% of women with HFs (n = 74) rating the ...
My research is mainly focused on the effects of cholesterol, saturated fat and statin drugs on health. If you know anyone who is worried about their cholesterol levels and heart disease, or has been told to take statin drugs you could send them a link to this website, and to my statin or cholesterol or heart disease books ...
Multiple epidemiologic and animal studies have established the link between obesity and increased risk for postmenopausal breast cancer. Because obesity is referred to as the epidemic of the 21st century with around 36% of the adult United States women defined as obese and another one third as overweight (1), this disease has a dramatic effect on quality of life as well as on life expectancy in the United States. The estimated increased risk for breast cancer is around 1.3- to 2-fold for obese postmenopausal women as compared with normal-weight postmenopausal women (2, 3). Several mechanisms have been proposed as being responsible for this increased risk for breast cancer. Among those, a well-studied mechanism is altered estrogen biosynthesis, mainly involving increased aromatase expression (4). Aromatase catalyzes the last steps of estrogen biosynthesis from androgens. Estrogen executes its effect mostly by binding to estrogen receptors (ER). Nuclear ERs function as transcription factors and ...
Studies done in different ethnic groups indicate that postmenopausal women are more salt-sensitive than premenopausal women, suggesting that decreases in ovarian hormone levels and increased sensitivity to dietary sodium may be important factors in the genesis of postmenopausal hypertension.4-6 The DS and DR rat strains developed by Dahl have been useful as an animal model for the study of salt-sensitive hypertension. One of the defects characterized in this form of hypertension is a blunted pressure-natriuresis relation, so that a higher blood pressure is needed to achieve the same level of sodium excretion. Short-term studies performed by Otsuka et al25 demonstrated this antinatriuretic shift in the pressure-natriuresis relation in DS rats compared with DR rats. OVX further impaired the pressure-natriuresis response in DS but not DR rats. These investigators, however, did not study whether OVX fostered hypertension.. In the present study, we have shown that in salt-sensitive DS rats, despite a ...
Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Womens Health Initiative Randomized Controlled Trial. Writing Group for the Womens Health Initiative Investigators. JAMA. 2002;288(3):321-333. Available at: http://jama.ama-assn.org/cgi/content/full/288/3/321 ...
Mammographic density (MD) is one of the strongest known breast cancer risk factors. Estrogen and progestin therapy (EPT) has been associated with increases in MD. Dense breast tissue is characterized by increased stromal tissue and (to a lesser degree) increased numbers of breast epithelial cells. It is possible that genetic factors modify the association between EPT and MD, and that certain genetic variants are particularly important in determining MD in hormone users. We evaluated the association between MD and 340 tagging single nucleotide polymorphisms (SNPs) from about 30 candidate genes in hormone metabolism/growth factor pathways among women who participated in the Norwegian Breast Cancer Screening Program (NBCSP) in 2004. We assessed MD on 2,036 postmenopausal women aged 50 to 69 years using a computer-assisted method (Madena, University of Southern California) in a cross-sectional study. We used linear regression to determine the association between each SNP and MD, adjusting for potential
Hundreds of human intervention studies evaluating the health effects of soyfoods and various soybean components have been conducted over the past 20 years. But a recent study published in the journal Stroke is among the most important and exciting. Led by Dr. Howard Hodis from the USC Keck School of Medicine in Los Angeles, the Womens Isoflavone Soy Health (WISH) trial is notable for its size, duration and primary health outcome of interest, which was the progression of subclinical atherosclerosis. In this 3-year study, 350 healthy postmenopausal women ages 45 to 92 were randomly assigned to groups consuming either 25 grams of soy protein per day or 25 grams of milk protein. The soy protein provided 99 milligrams of isoflavones, a type of phytoestrogen found in soybeans. Subclinical atherosclerosis can be assessed using ultrasound to measure the thickness of the carotid arteries-which are located on both sides of the neck beneath the jawline and provide the main blood supply to the brain. The ...
BACKGROUND: While observational studies have suggested that unopposed estrogens reduce the incidence of coronary disease in postmenopausal women, there are few data on the effect of combined therapy with estrogens and progestins--a regimen adopted in
For women exploring the diet and health connection, adding soyfoods and soy protein to the diet has just become an even better idea. It is well known that consuming 25 grams of soy protein per day will lower cholesterol and possibly blood pressure. And now, newly published research indicates it will also help postmenopausal women increase their strength. The combination of resistance exercise training and supplementing the diet with soy protein can increase strength, which should help to prevent age-related functional decline.
Millions of postmenopausal women are diagnosed with UTIs every year. Is there a cure? See what steps you can take to protect yourself.
Use of estrogen alone did not increase lung cancer mortality in postmenopausal women, according to a study published online August 13 in The Journal of the National Cancer Institute.
School of Nursing professor Ora Strickland let her audience in on the backstory of the Womens Health Initiative, a groundbreaking federal study.. In her Founders Week Distinguished Faculty Lecture on Feb. 2, Strickland provided insight into the "scientific and sociopolitical lessons learned" as a top consultant and insider on the National Institutes of Health study that ran from 1993 to 2005.. The WHI had its roots in the 1980s when more women were elected to Congress, Strickland said.. "There was a lot of concern about the lack of information on womens health," she explained. "These women [in Congress] began to notice that when the director of the NIH came to give his annual report for the budget, there was little focus on womens issues.". In 1990, the NIH Office of Research on Womens Health was established. And President George H.W. Bush appointed a woman head of NIH "for the first time ever.". "The focus was on the leading causes of morbidity, declining quality of life, mortality in ...
What explanation did you get about the bleeding? The RCOG guidelines for postmenopausal women presenting with cysts are very good (it was thought that I was pos...
Taking hormone drugs for more than ten years could help to dramatically reduce the risk of breast cancer recurrence, according to a landmark study.A randomised clinical trial involving nearly 2,000 women found that cancer recurrence dropped by a third in those who took hormone drugs for ten years rather than the standard five.Hormone therapy is given to the women with ER-positive breast cancer in order to stop the body from producing oestrogen, which helps to drive the growth of tumours in this type of breast cancer.
Select the postmenopausal patients with breast cancer who is confirmed by core needle biopsy and at the clinical stage T2-4N0-2M0.Treat them with 4 cycl
Health, ...Post-menopausal women who engage in moderate to vigorous exercise have... With an estimated 182460 new cases diagnosed in the United States in...Over 110000 post menopausal women were asked to rate their level of p...Dr. Peters concludes Our findings could help inform the mechanisms o...,Recent,,vigorous,exercise,is,associated,with,reduced,breast,cancer,risk,medicine,medical news today,latest medical news,medical newsletters,current medical news,latest medicine news
Healthy postmenopausal women who took 25 mg of a type of aromatase inhibitor called exemestane daily for two years experienced bone loss in their forearm and ankle, the study published in the journal Lancet found.
(HealthDay)-Inclusion of endogenous hormones in prediction models improves prediction of invasive breast cancer risk in postmenopausal women, according to a study published online Aug. 18 in the Journal of Clinical Oncology.
The U.S. Food and Drug Administrationon Friday approved Radius Health Incs drug to treatosteoporosis in postmenopausal women at high risk of fracture orthose who have failed other therapies.
After 18 years, the biggest randomized study on hormone therapy finds menopausal women who used it did not tend to die sooner, but they didnt tend to live longer either.
Lets face it. Despite the evidence that exercise is good for us, many of us in the U.S. are pretty sedentary and dont get the exercise we need. According to The Heart Truth, 40 percent of all women do not list exercise as one of their
Piqray® (alpelisib) is approved to treat postmenopausal women, and men with HR-positive or HER2-negative, advanced breast cancer with PIK3CA mutation.
1. Yoles I. et al. Efficacy and Safety of Standard versus Low Dose of Femarelle (Tofupill) for the Treatment of Menopausal Symptoms. J. of Clin Exper Obstet Gynecol 2004; 31(2):123-26.. 2. Labos G., Trakakis E. et al Efficacy and safety of DT56a (Femarelle) compared to hormone therapy in Greek postmenopausal women. J Endocrinol. Invest. 2013; 36(7):521-6. 3. Genazzani AR et al. Brain region responsiveness to DT56a (Femarelle) administration on allopregnanolone and opioid content in ovariectomized rats. Menopause 2009; 16(5):1037- 43.. 4. Genazzani A., Nachtigall L., Panay N. & Yoles I. Symposium: 2 Continents, 3 cultures, 4 countries, 2,000 women and Femarelle®; 13th World Congress on Menopause. Rome, Italy June 2011. 5. Nachtigall M. et al. A Prospective Study of DT56a (Femarelle) for the Treatment of Postmenopausal Vaginal Atrophy. Menopause book of abstract of the NAMS 22nd Annual Meeting, Sept, 2011, p. 55. 6. Yoles I. et al. Tofupill/Femarelle (DT56a) - a New Phyto-Selective Estrogen ...
As if the other symptoms of menopause arent bad enough, one of the major issues postmenopausal women face is a drastic increase in the risk of cardiovascular disease. Fortunately, there seems to be mounting evidence that consuming just two apples a day can have a significant effect in lowering cholesterol in as little as 3… Continue Reading. ...
Among postmenopausal women who have colon cancer, those carrying extra weight before their diagnosis appear to have an increased risk of dying, researchers found.
NIH Funding Opportunities and Notices in the NIH Guide for Grants and Contracts: Functional Characterization of Genetic Variants and Interactions: The Genes, Environment and Health Initiative (R21) RFA-DA-09-003. NIDA
1)recommendations by "expert"panels are subject to reversal due to the fragile and provisional nature of medical conventional wisdom. Physicians feel bad when they make certain recommendations ( e.g. HRT for postmenopausal women) and later learn they may have harmed their patients, but at least they thought they were doing the right thing based on the information available at the time. However, with P4P, " Shall we have the same solace if we make these decisions,not because we think they are right but for money? ...
A new study found that postmenopausal women who lost and regained weight had about 3.5 times higher risk of sudden cardiac death, and a 66% greater
Sara Pimental, MLIS, AHIP Spring 2005 - Volume 9 Number 2 Effective, evidence-based literature searching is easier if its kept simple. The basic steps are: A Clinical Question Arises Out of Care of the Patient A 60-year-old, postmenopausal woman
A recent study among asymptomatic post-menopausal women found an adjusted hazard ratios for CHD events of 1.55 (95% CI, 1.14-2.11) for minor, 3.01 (95% CI, 2.03-4.46) for major ECG abnormalities.[1] This study used a well defined list of major and minor ECG abnormalities that can be used to get a feel for major and minor ECG abnormalities: Major ECG abnormalities[1][2]: ...
A recent study among asymptomatic post-menopausal women found an adjusted hazard ratios for CHD events of 1.55 (95% CI, 1.14-2.11) for minor, 3.01 (95% CI, 2.03-4.46) for major ECG abnormalities.[1] This study used a well defined list of major and minor ECG abnormalities that can be used to get a feel for major and minor ECG abnormalities: Major ECG abnormalities[1][2]: ...
I have seen some crazy things when it comes to study interpretation but this one may take the cake. The full article is here, but here are the high points: The study looked at weight loss in post-menopausal women during and after a five month diet. They found that: the women lost about 12% of…
Find the training resources you need for all your activities. Studyres contains millions of educational documents, questions and answers, notes about the course, tutoring questions, cards and course recommendations that will help you learn and learn.
Although widely used for its anti-estrogen properties tamoxifen has estrogen like effects on a number of tissues including bone and liver. Previous studies suggest a preservation of lumbar spine density in postmenopausal women but the effect on the hip had not been addressed. To determine whether tamoxifen prevents bone loss in the early postmenopausal period bone mineral density at the lumbar spine and femoral neck was measured using dual energy X-ray absorptiometry at presentation and 6 monthly thereafter for 1 year in a prospective controlled study. Also indices of bone turnover, serum osteocalcin and urinary hydroxyproline excretion, were assessed. Fifteen early postmenopausal women with Stage I or II breast cancer treated with tamoxifen and 21 normal postmenopausal women were studied. Sex hormone binding globulin and antithrombin III levels in serum were also measured as indices of the hepatic estrogenic activity. Tamoxifen (20 mg daily) prevented bone loss at the femoral neck and lumbar spine.
OBJECTIVE: To examine the effects of hormone replacement therapy (HRT) on lipid metabolism, glycemic control, total body and central abdominal fat, blood pressure (BP), and arterial pulse wave velocity (APWV) in overweight postmenopausal females with type 2 diabetes. RESEARCH DESIGN AND METHODS: This was a 12-month prospective study of 14 subjects (mean +/- SD age 57.5+/-5.6 years, BMI 29.5+/-4.8 kg/m2) randomized to 6 months of observation or HRT before crossover. HRT consisted of 2 months of conjugated equine estrogen (CEE) 0.625 mg daily, followed by 4 months CEE and medroxyprogesterone 5 mg daily. Measures included anthropometry, fasting glucose, insulin, HbA1c, total and HDL cholesterol, triglycerides, apolipoprotein B, LDL particle size, nonesterified fatty acids (NEFA), sex hormone-binding globulin, resting energy expenditure (REE), total and central abdominal fat (by dual-energy X-ray absorptiometry), resting BP, APWV (by applanation tonometry), physical activity, well-being, and sexual function
Studies conducted in Asian populations have suggested that high consumption of soy-based foods that are rich in isoflavone phytoestrogens is associated with a reduced risk of breast cancer. In the prospectively examined associations between the risk of postmenopausal invasive breast cancer and dietary intakes of four plant lignans (pinoresinol, lariciresinol, secoisolariciresinol, and matairesinol) and estimated exposure to two enterolignans (enterodiol and enterolactone), as measured with a self-administered diet history questionnaire, among 58,049 postmenopausal French women who were not taking soy isoflavone supplements, posted in PubMed, showed that hgh dietary intakes of plant lignans and high exposure to enterolignans were associated with reduced risks of ER- and PR-positive postmenopausal breast cancer in a Western population that does not consume a diet rich in soy ...
TUESDAY, Oct. 6, 2015 (HealthDay News) -- Hormone replacement therapy may be good for a womans kidneys, a preliminary study suggests.. "The risks and benefits of hormone replacement therapy in postmenopausal women are still an area of active debate, and the effect of hormone replacement therapy on the kidney has shown variable results," said study author Dr. Andrea Kattah of the Mayo Clinic in Minnesota.. Her study compared nearly 700 older women taking hormone replacements with more than 1,500 who were not.. Rates of two indicators of kidney disease -- microalbuminuria and decreased estimated glomerular filtration rate -- were much lower in the women taking hormone replacements, the study found.. Microalbuminuria occurs with higher-than-normal levels of a protein called albumin in urine that could be a sign of kidney damage.. After they adjusted for known kidney and heart disease risk factors, the researchers found that hormone replacement was still strongly associated with lower rates of ...
Published on: March 2, 2012. by Dr Ananya Mandal, MD for News Medical:. A new study finds that older women who take in substantial amount of trans fats are more likely than their counterparts to suffer an ischemic stroke.. However, the risk of stroke associated with trans fat intake was lower among women taking aspirin, according to the findings from University of North Carolina at Chapel Hill researchers. The report, "Trans Fat Intake, Aspirin and Ischemic Stroke Among Postmenopausal Women," was published today online in the journal Annals of Neurology.. Researchers from the UNC Gillings School of Global Public Health studied women who were enrolled in the Womens Health Initiative Observational Study. From 1994 to 2005, 1,049 new cases of ischemic stroke were documented.. The researchers looked at 87,025 generally healthy postmenopausal women aged 50 to 79 found that those whose diets contained the largest amounts of trans fats were 39 percent more likely to have an ischemic stroke (clots in ...
Substantial evidence suggests that the estrogen status has significant impact on cardiovascular morbidity and mortality.23 24 In particular, ERT lowers cardiovascular mortality and improves vascular reactivity in postmenopausal women.23 24 25 26 The underlying mechanisms are incompletely understood.27 Activation of the renin-angiotensin system, or high renin levels, on the other hand, has been implicated to be an adverse factor in vascular and cardiac pathophysiology.14 In the present study, several lines of evidence suggest that the estrogen status affects the level of renin in the circulation. First, women replacing estrogen during menopause presented with significantly lower renin levels than those not using such therapy; second, women with premenopausal circulating estradiol levels displayed renin levels that were lower than found in women with postmenopausal estradiol levels; third, these differences were evident also in women using ACE inhibitors (despite feedback activation of renin by ...
TY - JOUR. T1 - Adjuvant endocrine therapy in postmenopausal breast cancer. AU - Ingle, James N.. PY - 2003/1/1. Y1 - 2003/1/1. N2 - Adjuvant endocrine therapy with tamoxifen has a clearly established benefit in postmenopausal women with resected early breast cancer that expresses the estrogen receptor and/or progesterone receptor. Whereas there is a vast and long experience with tamoxifen, the major focus of clinical trials over the past 6 years has involved the study of the third-generation aromatase inhibitors. Recently published data from the Arimidex, Tamoxifen, Alone or in Combination (ATAC) trial, which involved only postmenopausal women and is the largest adjuvant trial ever conducted, has demonstrated superior efficacy for anastrozole over tamoxifen alone or in combination with anastrozole. These data have engendered a great deal of discussion as to whether they provide a sufficient basis for changing the standard of practice in terms of choice of agent. Currently, a case can be made ...
BACKGROUND: The aromatase inhibitor letrozole is a more effective treatment for metastatic breast cancer and more effective in the neoadjuvant setting than tamoxifen. We compared letrozole with tamoxifen as adjuvant treatment for steroid-hormone-receptor-positive breast cancer in postmenopausal women. METHODS: The Breast International Group (BIG) 1-98 study is a randomized, phase 3, double-blind trial that compared five years of treatment with various adjuvant endocrine therapy regimens in postmenopausal women with hormone-receptor-positive breast cancer: letrozole, letrozole followed by tamoxifen, tamoxifen, and tamoxifen followed by letrozole. This analysis compares the two groups assigned to receive letrozole initially with the two groups assigned to receive tamoxifen initially; events and follow-up in the sequential-treatment groups were included up to the time that treatments were switched. RESULTS: A total of 8010 women with data that could be assessed were enrolled, 4003 in the letrozole ...
OBJECTIVE: To examine whether binding of [3H]paroxetine to the platelet serotonin transporter or binding of [3H]lysergic acid diethylamide (LSD) to the platelet 5-HT(2A) receptor are influenced by postmenopausal estrogen/progestogen treatment. METHODS: Twenty-three postmenopausal women with climacteric symptoms completed this double-blind, randomized, crossover study. The women received 2 mg of estradiol continuously during four 28-day cycles. In the last 14 days of each cycle, 10 mg of medroxyprogesterone acetate, 1 mg of norethindrone acetate, or placebo was given. Before treatment, as well as once during the last week of each treatment, blood samples were collected for analysis of [3H]LSD and [3H]paroxetine binding. The power of the study setup was 81%. The study had an effect size of 0.36, corresponding to the ability to detect a 15% difference in [3H]paroxetine and [3H]LSD binding between treatments with alpha =.05 and beta =.20, based on a previously reported standard deviation within ...
In an analysis of the Breast International Group (BIG) 1-98 trial reported in the Journal of Clinical Oncology, Chirgwin et al found that poorer adherence to endocrine therapy was associated with poorer disease-free survival in postmenopausal women with hormone receptor-positive breast cancer receiving adjuvant tamoxifen, letrozole, or sequential letrozole/tamoxifen or tamoxifen/letrozole for 5 years.. Study Details. The study analyzed the effects of early cessation of treatment (, 36 months vs ≥ 36 months) and treatment compliance score , 90% on disease-free survival among 6,144 patients receiving at least one dose of study drug. Compliance was defined as taking at least 80% of pills in a drug pack with no breaks longer than 1 week.. Effects of Lower Adherence. On multivariate analysis, early cessation of letrozole (hazard ratio [HR] = 1.45, P = .01), tamoxifen/letrozole (HR = 1.56, 95% confidence interval [CI] = 1.21-2.01), and letrozole/tamoxifen (HR = 1.57, 95% CI = 1.21-2.03) were ...
ESMO 2016. Recommended first-line treatments for postmenopausal women with hormone receptor-positive advanced/metastatic breast cancer include third-generation aromatase inhibitors (ie, anastrozole) or tamoxifen. Fulvestrant, is a complete estrogen receptor (ER) antagonist approved for the treatment of ER+ advanced breast cancer after aromatase inhibitors have failed. Although a previous phase 2 study was unable to show a difference in clinical benefit rate (CBR) between first-line fulvestrant and anastrozole in these patients, "the median time to progression was significantly increased in patients receiving fulvestrant, which unusually translated into increased overall survival [OS]," said Dr Matthew Ellis of Houston, TX, an author of the subsequent FALCON study.. The FALCON study was a phase 3, randomized, double-blind, multicenter trial designed to confirm the superiority of fulvestrant over anastrozole in postmenopausal women with ER+ and/or progesterone receptor-positive (PR+) advanced ...
A recent study in conducted in Canada reveals that breast cancer patients treated with the drug Femara® (letrozole) several years after completing treatment with tamoxifen (Nolvadex®) have a reduced risk of a recurrence. These findings were published in the Journal of Clinical Oncology.. The majority of breast cancers are hormone receptor-positive. These cancers are stimulated to grow by the circulating female hormones estrogen and/or progesterone. Women with hormone receptor-positive breast cancer are often treated with hormonal therapy, such as tamoxifen, for five years following completion of chemotherapy and radiation. Hormonal therapies act by blocking the estrogen from reaching the breast cancer cells, slowing or halting their growth. Femara is also an estrogen-blocking drug that is commonly prescribed to postmenopausal women diagnosed with hormone receptor-positive breast cancer.. Previous research indicates that 50% of breast cancer recurrences and deaths occur five or more years after ...
Looking for online definition of Sex hormone binding globulin in the Medical Dictionary? Sex hormone binding globulin explanation free. What is Sex hormone binding globulin? Meaning of Sex hormone binding globulin medical term. What does Sex hormone binding globulin mean?

Post Menopause Clinical Research Trials | CenterWatchPost Menopause Clinical Research Trials | CenterWatch

Post Menopause Clinical Trials. A listing of Post Menopause medical research trials actively recruiting patient volunteers. ... Post Menopause Study Currently we have the following studies: Birth Control/ Contraceptive Vaginal Atrophy Pain During ...
more infohttps://www.centerwatch.com/clinical-trials/listings/condition/274/post-menopause/

What is Postmenopause?What is Postmenopause?

Postmenopause and estrogen, postmenopausal women are at higher risk for these health conditions, safe and effective ... Learn about post menopause symptoms. Bioidentical menopause and natural treatment. Best source of progesterone and natural ... During postmenopause, women need to maintain an optimal weight. If you are overweight, you should exercise daily to control ... With exercise, postmenopause women have better sex lives. Exercise is known to improve your mood, and it boosts your immune ...
more infohttp://www.safemenopausesolutions.com/postmenopause.html

PatientsLikeMe | Postmenopause symptoms, treatments & patient forums | PatientsLikeMePatientsLikeMe | Postmenopause symptoms, treatments & patient forums | PatientsLikeMe

84 patients with postmenopause experience fatigue, depressed mood, pain, anxious mood, and insomnia and use Buprenorphine patch ... Find the most comprehensive real-world symptom and treatment data on postmenopause at PatientsLikeMe. ... What is postmenopause?. The time of a womans life following menopause is called postmenopause. At this time symptoms ... 0 evaluations from postmenopause patients report that they could not tell effectiveness of Hydroxyzine for anxious mood (0%) ...
more infohttps://www.patientslikeme.com/conditions/1623-postmenopause

Hormonal Therapy and Post-MenopauseHormonal Therapy and Post-Menopause

... Post-menopause, or the period after menopause, begins when a woman has not had a menstrual ... During post-menopause, many women find that they feel liberated. They no longer have to worry about their menstrual cycles and ... It is not uncommon for women in post-menopause to go back to school, start a business, write a book or begin traveling in ... A woman in recovery has a doubly hard task during menopause and post-menopause. She must learn how to navigate not only the ...
more infohttp://www.orchidrecoverycenter.com/hormone-therapy/hormonal-therapy-and-post-menopause/

Change in marital status post-menopause may impact health | EurekAlert! Science NewsChange in marital status post-menopause may impact health | EurekAlert! Science News

Change in marital status post-menopause may impact health. University of Arizona. Journal. Journal of Womens Health. Keywords ... change-marital-status-postmenopause-may-impact-health Related Journal Article. http://dx.. doi.. org/. 10.. 1089/. jwh.. 2016. ...
more infohttps://www.eurekalert.org/pub_releases/2017-02/uoa-cim020617.php

Dont Believe These Post-Menopause Sex Myths | Lifescript.comDon't Believe These Post-Menopause Sex Myths | Lifescript.com

Post-menopause myth 1: Your desire for sex will end with your periods.. The facts: Desire levels differ among women. "Women of ... Post-menopause myth 4: You can stop worrying about birth control and safe sex. The facts: Want a baby to liven up your middle ... Post-menopause myth 6: Youre too old to kick things up a notch. The facts: The longer a couple has been together, the greater ... Post-menopause myth 7: You can take a break from sex now without negative consequences later. The facts: "The principle of use ...
more infohttp://www.lifescript.com/health/centers/vaginal_atrophy/articles/dont_believe_these_post_menopause_sex_myths.aspx

Postmenopause | definition of postmenopause by Medical dictionaryPostmenopause | definition of postmenopause by Medical dictionary

... postmenopause explanation free. What is postmenopause? Meaning of postmenopause medical term. What does postmenopause mean? ... Looking for online definition of postmenopause in the Medical Dictionary? ... postmenopause. postmenopause. (pōst″mĕn′ō-pawz″) [″ + ″] The phase of a womans life that begins 1 year after her final ... But what you may not know is that the first three to five years postmenopause are the most crucial for bones.. Best exercises ...
more infohttp://medical-dictionary.thefreedictionary.com/postmenopause

Menopause, Perimenopause and Postmenopause Living With | Cleveland ClinicMenopause, Perimenopause and Postmenopause Living With | Cleveland Clinic

Menopause, Perimenopause and Postmenopause Menu Overview Diagnosis and Tests Management and Treatment Outlook / Prognosis ...
more infohttps://my.clevelandclinic.org/health/diseases/15224-menopause-perimenopause-and-postmenopause/living-with

NAMS 2015 Conference: Diabetes Management in Postmenopause | EmpowHER - Womens Health OnlineNAMS 2015 Conference: Diabetes Management in Postmenopause | EmpowHER - Women's Health Online

Its no surprise that diet, nutrition and exercise are regarded as the most important factors in not only reducing diabetes, but controlling it.
more infohttp://www.empowher.com/diabetes/content/nams-2015-conference-diabetes-management-postmenopausal-women

Smoking Before Menopause Increases Breast Cancer Risk, Post Menopause May 
Lower RiskSmoking Before Menopause Increases Breast Cancer Risk, Post Menopause May Lower Risk

Smoking Before Menopause Increases Breast Cancer Risk, Post Menopause May Lower Risk. Never smoking and passive smoking in ...
more infohttp://seniorjournal.com/NEWS/Health/2011/20110124-SmokingBeforeMenopause.htm

Postmenopause Weight Gain and Increase in Bad Cholesterol May Contribute to Artery Damage | EmaxHealthPostmenopause Weight Gain and Increase in Bad Cholesterol May Contribute to Artery Damage | EmaxHealth

Postmenopause Weight Gain and Increase in Bad Cholesterol May Contribute to Artery Damage. ...
more infohttps://www.emaxhealth.com/70/2002.html

Does Risk of Ovarian Cancer Increase during Postmenopause?Does Risk of Ovarian Cancer Increase during Postmenopause?

Menopause and postmenopause can be scary times for women who dont know what to expect. Learn about the risk of ovarian cancer ... If you want to learn more about postmenopause, click on the link below to find out about postmenopause treatments. ... Are Ovarian Cysts Common in Postmenopause?. Many women appreciate finishing up menopause and entering postmenopause because ... Menopause and postmenopause can be alarming for women who dont know what to expect. With hormones and emotions running wild it ...
more infohttps://www.34-menopause-symptoms.com/articles/does-risk-of-ovarian-cancer-increase-post-menopause.htm

Early postmenopause women can benefit from hormone therapyEarly postmenopause women can benefit from hormone therapy

In the early postmenopause group, HT slowed the development of atherosclerosis. In the late postmenopause group, it did not. ... Early postmenopause women can benefit from hormone therapy. ASK DOCTOR K Anthony L. Komaroff, M.D. Published 8:48 p.m. PT July ... Early postmenopause women can benefit from hormone therapy. Hormone therapy usually involves a combination of both estrogens ( ... Early postmenopause women can benefit from hormone therapy Hormone therapy usually involves a combination of both estrogens ( ...
more infohttps://www.thecalifornian.com/story/life/2016/07/18/early-postmenopause-women-can-benefit-hormone-therapy/87238664/

Post Menopause: The Last Phase Of Your Menstrual Cycle!Post Menopause: The Last Phase Of Your Menstrual Cycle!

Is there any chance for bleeding in post menopause stage?. Yes! There is a chance for vaginal bleeding during your post ... How can you know that you are in the stage of post menopause?. If you lack the symptoms of menopause like hot flashes, ... Post menopause bleeding can also occur during certain emotional events like if you are meeting your children after a long gap ... Post menopause is the last stage in four stage process of menstruation, which brings an end to your reproductive cycle. ...
more infohttps://www.womenhealthzone.com/menopause/post-menopause-the-last-phase-of-your-menstrual-cycle/

Postmenopause: Vaginal estrogenization | Ob.Gyn. NewsPostmenopause: Vaginal estrogenization | Ob.Gyn. News

A study that examined the prevalence and correlates of vaginal estrogenization in postmenopausal women in the United States found that in every age group, vaginal estrogenization was _______________ among postmenopausal nonusers of hormone therapy in the 2005 to 2006 cohort, compared with historical clinical data. ...
more infohttps://mdedge.com/obgynnews/quiz/4444/menopause/postmenopause-vaginal-estrogenization?channel=247

Post Menopause Cholesterol - the virtual ObGyn officePost Menopause Cholesterol - the virtual ObGyn office

Post Menopause Cholesterol. In 2009, the organizers of a medical study published in the Journal of the American College of ...
more infohttps://gynob.com/post-meno-cholesterol.htm

Regular Walking May Protect Against Heart Failure Post Menopause - American College of CardiologyRegular Walking May Protect Against Heart Failure Post Menopause - American College of Cardiology

YOU ARE HERE: Home , About ACC , Press Releases , Regular-Walking-May-Protect-Against-Heart-Failure-Post-Menopause ... Regular Walking May Protect Against Heart Failure Post Menopause. Brisk walks lasting 40 minutes or more, two to three times ...
more infohttps://www.acc.org/About-ACC/Press-Releases/2018/02/27/11/53/Regular-Walking-May-Protect-Against-Heart-Failure-Post-Menopause

Post Menopause - Australian Menopause CentrePost Menopause - Australian Menopause Centre

About Post Menopause. What is Post Menopause?. Postmenopause is the fourth and last stage of the menopause process. Technically ... Post Menopause 11.11.2015 Postmenopause can come across as an enigmatic time of life -the first time in decades that a woman ... Understanding Post Menopause. When women reach postmenopause, they will regain a sense of control of their bodies. By then, the ... External Causes of Post Menopause. Even though hormone changes are at the very foundation of postmenopause there are a number ...
more infohttps://www.menopausecentre.com.au/information-centre/articles/post-menopause/

Enlarged pelvic veins post menopause - Things You Didnt KnowEnlarged pelvic veins post menopause - Things You Didn't Know

Post menopause) l have had brown blood after sex. Should l the wait and see if it happens again or go to my gyn? ... Post menopause but LH and FSH are above upper limits. 81.4 and 197.6 respectively. Normal or cause for concern? (no hrt) ... 15 yrs post menopause. I do not know my biological mother, or her health history. Should I get the brca2 test? ... Post menopause: What? You are an 18 year-old post menopausal male? Please take the time to ask a proper question if you are ...
more infohttps://www.healthtap.com/topics/enlarged-pelvic-veins-post-menopause

Post menopause ovarian lower back pain - Things You Didnt KnowPost menopause ovarian lower back pain - Things You Didn't Know

Enlarged pelvic veins post menopause * Pelvic pain in post menopause * Do fibroids cause pain in lower left side of abdomen of ...
more infohttps://www.healthtap.com/topics/post-menopause-ovarian-lower-back-pain

Search: normal expression:Uterus, post-menopause;Cells in endometrial stroma;Negative,Weak,Moderate,Strong - The Human Protein...Search: normal expression:Uterus, post-menopause;Cells in endometrial stroma;Negative,Weak,Moderate,Strong - The Human Protein...

annotations (the reliablity of the annotated protein expression using immunohistochemically (IH) stained on human tissues, the reliablity of the annotated protein expression in immunofluorescently (IF) stained human cell lines, tissue specificity (the distribution of antibody staining or protein expression in human cell types), cell line specificity (the distribution of RNA abundance in cell lines) and subcellular location (based on immunofluorescent staining of cell lines ...
more infohttp://www.proteinatlas.org/search/normal_expression%3AUterus,+post-menopause%3BCells+in+endometrial+stroma%3BNegative%2CWeak%2CModerate%2CStrong

Cortisol Levels during the Menopausal Transition and Early Postmenopause: Observations from the Seattle Midlife Womens Health...Cortisol Levels during the Menopausal Transition and Early Postmenopause: Observations from the Seattle Midlife Women's Health...

Early postmenopause (PM) was within five years of the FMP. The staging method has been validated against data from other ... These findings suggest that overnight cortisol levels during the menopausal transition and early postmenopause are more likely ... Cortisol Levels during the Menopausal Transition and Early Postmenopause: Observations from the Seattle Midlife Womens Health ... Symptoms during the Menopausal Transition and Early Postmenopause and their Relation to Endocrine Levels over Time: ...
more infohttp://pubmedcentralcanada.ca/pmcc/articles/PMC2749064/
  • This article will provide an explanation of some of the key changes that your body may experience during this phase, and offers suggestions for ways in which you can look after your health postmenopause. (menopausecentre.com.au)
  • Data from patients with postmenopause, who reported starting treatments within the last 5 years. (patientslikeme.com)
  • If you want to learn more about postmenopause , click on the link below to find out about postmenopause treatments. (34-menopause-symptoms.com)
  • To determine the effectiveness of using the medicinal form of the complex preparation Polygynax Virgo in treatment and prevention of vulvovaginal infections in postmenopause. (med-expert.com.ua)
  • Polygynax is highly effective in treatment of nonspecific colpitis in postmenopause. (med-expert.com.ua)
  • Even though hormone changes are at the very foundation of postmenopause there are a number of external factors that could throw a woman into her postmenopause years earlier in her life. (menopausecentre.com.au)
  • Postmenopause can come across as an enigmatic time of life -the first time in decades that a woman does not have the capacity to reproduce. (menopausecentre.com.au)
  • Improving the amount of nutrition in your diet will provide many benefits, and will help to reduce health risks that you may face postmenopause. (menopausecentre.com.au)
  • Making healthy lifestyle changes during postmenopause will greatly reduce a woman's risk of heart disease and cancer. (menopausenow.com)
  • Does Risk of Ovarian Cancer Increase during Postmenopause? (34-menopause-symptoms.com)
  • Continue reading to find out what ovarian cancer is, what the signs are, and why it is thought that the risk of ovarian cancer increases throughout postmenopause . (34-menopause-symptoms.com)